Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ted Baker to appoint administrators

(Sharecast News) - Fashion brand Ted Baker is set to call in administrators, it emerged on Tuesday. Authentic Brands Group (ABG) owns the Ted Baker brand and licenses it to No Ordinary Designer Label, which trades as Ted Baker in the UK. ABG confirmed that the independent director of NODL has called in the administrators.

ABG pointed to "damage done" to Ted Baker during the time Dutch company AARC was running its stores and e-commerce business in Europe, highlighting a "significant level of arrears" built up.

Ted Baker has 86 stores in the UK and hundreds of jobs are at risk.

John McNamara, chief strategy and transition officer for Authentic Brands Group, said: "We wish that there could have been a better outcome for the Ted Baker employees and stakeholders.

"It is hopefully some consolation for customers that NODL will continue to trade online and in stores.

"We remain focused on securing a new partner to uphold and grow the Ted Baker brand in the UK and Europe where it began."

Share this article

Related Sharecast Articles

Goldman Sachs downgrades SSP to 'sell', prefers WH Smith
(Sharecast News) - Goldman Sachs downgraded SSP on Monday to 'sell' from 'neutral' "on a relative basis" as it took a look at European travel concessions.
UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.